CN104311473A - 一种哌啶类化合物及其制备方法 - Google Patents
一种哌啶类化合物及其制备方法 Download PDFInfo
- Publication number
- CN104311473A CN104311473A CN201410227512.1A CN201410227512A CN104311473A CN 104311473 A CN104311473 A CN 104311473A CN 201410227512 A CN201410227512 A CN 201410227512A CN 104311473 A CN104311473 A CN 104311473A
- Authority
- CN
- China
- Prior art keywords
- piperidines
- preparation
- consumption
- weight ratio
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title abstract 4
- -1 Piperidine compound Chemical class 0.000 title abstract 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims abstract description 42
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims abstract description 24
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 claims abstract description 24
- 150000001875 compounds Chemical class 0.000 claims abstract description 17
- 239000003513 alkali Substances 0.000 claims abstract description 14
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims abstract description 11
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000012312 sodium hydride Substances 0.000 claims abstract description 11
- 229910000104 sodium hydride Inorganic materials 0.000 claims abstract description 11
- 238000006114 decarboxylation reaction Methods 0.000 claims abstract description 8
- 239000002253 acid Substances 0.000 claims abstract description 7
- 150000003053 piperidines Chemical class 0.000 claims description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 16
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 11
- 239000005695 Ammonium acetate Substances 0.000 claims description 11
- 229940043376 ammonium acetate Drugs 0.000 claims description 11
- 235000019257 ammonium acetate Nutrition 0.000 claims description 11
- 229940125904 compound 1 Drugs 0.000 claims description 11
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 11
- QUSNBJAOOMFDIB-UHFFFAOYSA-N monoethyl amine Natural products CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 claims description 6
- 239000012467 final product Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 238000005481 NMR spectroscopy Methods 0.000 claims description 2
- 238000004176 ammonification Methods 0.000 claims description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 239000013067 intermediate product Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 7
- 230000035484 reaction time Effects 0.000 abstract description 2
- ZFDIRQKJPRINOQ-HWKANZROSA-N Ethyl crotonate Chemical compound CCOC(=O)\C=C\C ZFDIRQKJPRINOQ-HWKANZROSA-N 0.000 abstract 1
- 239000007795 chemical reaction product Substances 0.000 abstract 1
- 238000006264 debenzylation reaction Methods 0.000 abstract 1
- ZFDIRQKJPRINOQ-UHFFFAOYSA-N transbutenic acid ethyl ester Natural products CCOC(=O)C=CC ZFDIRQKJPRINOQ-UHFFFAOYSA-N 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- 239000002994 raw material Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 238000001953 recrystallisation Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410227512.1A CN104311473B (zh) | 2014-05-27 | 2014-05-27 | 一种哌啶类化合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410227512.1A CN104311473B (zh) | 2014-05-27 | 2014-05-27 | 一种哌啶类化合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104311473A true CN104311473A (zh) | 2015-01-28 |
CN104311473B CN104311473B (zh) | 2016-09-28 |
Family
ID=52366821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410227512.1A Active CN104311473B (zh) | 2014-05-27 | 2014-05-27 | 一种哌啶类化合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104311473B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105777615A (zh) * | 2016-04-07 | 2016-07-20 | 戊言医药科技(上海)有限公司 | 4-吗啉代哌啶的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0417698B1 (de) * | 1989-09-12 | 1996-03-13 | Hoechst Aktiengesellschaft | Aminosäurederivate mit reninhemmenden Eigenschaften, Verfahren zu deren Herstellung, diese enthaltende Mittel und deren Verwendung |
CN1420881A (zh) * | 2000-03-17 | 2003-05-28 | 布里斯托尔-迈尔斯斯奎布药品公司 | 作为基质金属蛋白酶和TNF-α抑制剂的β-氨基酸衍生物 |
US20040072802A1 (en) * | 2002-10-09 | 2004-04-15 | Jingwu Duan | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha |
WO2010091164A1 (en) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Inhibitors of glucosylceramide synthase |
-
2014
- 2014-05-27 CN CN201410227512.1A patent/CN104311473B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0417698B1 (de) * | 1989-09-12 | 1996-03-13 | Hoechst Aktiengesellschaft | Aminosäurederivate mit reninhemmenden Eigenschaften, Verfahren zu deren Herstellung, diese enthaltende Mittel und deren Verwendung |
CN1420881A (zh) * | 2000-03-17 | 2003-05-28 | 布里斯托尔-迈尔斯斯奎布药品公司 | 作为基质金属蛋白酶和TNF-α抑制剂的β-氨基酸衍生物 |
US20040072802A1 (en) * | 2002-10-09 | 2004-04-15 | Jingwu Duan | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha |
WO2010091164A1 (en) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Inhibitors of glucosylceramide synthase |
Non-Patent Citations (1)
Title |
---|
ACS: "CAS RN:1281674-64-3", 《STN REGISTRY数据库》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105777615A (zh) * | 2016-04-07 | 2016-07-20 | 戊言医药科技(上海)有限公司 | 4-吗啉代哌啶的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104311473B (zh) | 2016-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106928236B (zh) | 一种瑞博西尼的合成工艺 | |
WO2017190609A1 (zh) | 一种高效合成西他沙星中间体(7s)-5-氮杂螺[2.4]庚烷-7-基氨基甲酸叔丁酯的制备方法 | |
CN105085484B (zh) | 一种富马酸沃诺拉赞的制备方法 | |
CN104910158B (zh) | 具有生物活性的5,6,7,8‑四氢吡啶并[3,4‑d]嘧啶化合物及其制备方法和应用 | |
Kolahdouzan et al. | Visible-light mediated carbonyl trifluoromethylative amination as a practical method for the synthesis of β-trifluoromethyl tertiary alkylamines | |
CN101638389A (zh) | 一种含萘酰亚胺结构的多胺衍生物及其制备方法和应用 | |
CN103012268B (zh) | 一种伊伐布雷定制备方法 | |
CN107602559A (zh) | 一种通过迈克尔加成引发的不对称环丙化合成手性三元碳环核苷的方法 | |
CN103880745A (zh) | 一种6-溴-1,2,3,4-四氢异喹啉-1-甲酸的化学合成方法 | |
CN104311473B (zh) | 一种哌啶类化合物及其制备方法 | |
CN104649966A (zh) | 一种有机中间体5-氰基-3甲基吡啶甲酸的合成方法 | |
CN101519374B (zh) | 一种手性吡啶类芳环氨基醇的衍生物的合成方法及其部分中间产物与最终产物 | |
CN105272921A (zh) | 一种制备Ceritinib的方法及其中间体化合物 | |
CN104774161B (zh) | 多肽、蛋白质peg修饰剂合成方法 | |
CN103864877A (zh) | 一种醋酸阿比特龙的制备方法 | |
CN109761959B (zh) | 一种Abemaciclib甲磺酸盐的合成方法 | |
CN107739328B (zh) | 用于合成巴瑞替尼的关键中间体1的制备方法 | |
CN106866624B (zh) | 一种卡比替尼的化学合成方法 | |
CN103242244B (zh) | 一种卡奈替尼的制备方法 | |
CN105523958B (zh) | 一种制备二芳基硫代乙内酰脲衍生物关键中间体的方法 | |
CN104230974B (zh) | 一种吡咯并吡啶类化合物及其制备方法 | |
CN103980206B (zh) | 一种嘧啶乙胺类化合物及其制备方法 | |
KR101453413B1 (ko) | 알파-카르볼린 유도체의 제조방법 | |
JP6105631B2 (ja) | 1,4−保護9−ヒドロキシ−5−オキソ−1,4−ジアザ−スピロ[5.5]ウンデカンの立体選択的合成方法 | |
CN101723879A (zh) | 一种合成(r)-3-哌啶乙酸乙酯盐酸盐的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: The 300000 Tianjin economic and Technological Development Zone Haiyun Street No. 80 plant No. 17 A6-8 Applicant after: SPHINX SCIENTIFIC LABORATORY (TIANJIN) CO.,LTD. Address before: 300000 Tianjin Binhai New Area Haiyun Street No. 80 No. 17 building A6-8 Applicant before: SPHINX SCIENTIFIC LABORATORY Corp. |
|
COR | Change of bibliographic data | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Piperidine compound and preparation method thereof Effective date of registration: 20190926 Granted publication date: 20160928 Pledgee: Tianjin Binhai rural commercial bank Limited by Share Ltd. Pledgor: SPHINX SCIENTIFIC LABORATORY (TIANJIN) CO.,LTD. Registration number: Y2019120000007 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200910 Granted publication date: 20160928 Pledgee: Tianjin Binhai rural commercial bank Limited by Share Ltd. Pledgor: SPHINX SCIENTIFIC LABORATORY (TIANJIN) Co.,Ltd. Registration number: Y2019120000007 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The invention relates to a piperidine compound and a preparation method thereof Effective date of registration: 20210526 Granted publication date: 20160928 Pledgee: Tianjin Binhai rural commercial bank Limited by Share Ltd. Pledgor: SPHINX SCIENTIFIC LABORATORY (TIANJIN) Co.,Ltd. Registration number: Y2021120000020 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220519 Granted publication date: 20160928 Pledgee: Tianjin Binhai rural commercial bank Limited by Share Ltd. Pledgor: SPHINX SCIENTIFIC LABORATORY (TIANJIN) CO.,LTD. Registration number: Y2021120000020 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Piperidine compound and its preparation method Effective date of registration: 20220525 Granted publication date: 20160928 Pledgee: Tianjin Binhai rural commercial bank Limited by Share Ltd. Pledgor: SPHINX SCIENTIFIC LABORATORY (TIANJIN) CO.,LTD. Registration number: Y2022120000023 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230612 Granted publication date: 20160928 Pledgee: Tianjin Binhai rural commercial bank Limited by Share Ltd. Pledgor: SPHINX SCIENTIFIC LABORATORY (TIANJIN) CO.,LTD. Registration number: Y2022120000023 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A piperidine compound and its preparation method Effective date of registration: 20230703 Granted publication date: 20160928 Pledgee: Tianjin Binhai rural commercial bank Limited by Share Ltd. Pledgor: SPHINX SCIENTIFIC LABORATORY (TIANJIN) CO.,LTD. Registration number: Y2023120000052 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |